Expanded facilities PharmaForce has recently expanded facilities in Ohio, indicating capacity growth and potential hardware, cleanroom, and manufacturing upgrades that may require vendor partnerships, equipment, facility services, and compliance support.

Sterile injectable focus Specialization in sterile injectables presents opportunities for aseptic filling, containment, fill-finish outsourcing, quality systems, and regulatory consulting suited to pharma manufacturing partners and CROs seeking experts in this niche.

Private-label backing As part of a Daiichi Sankyo Group company through Luitpold Pharmaceuticals, PharmaForce could benefit from and offer integrated supply chain, distribution, and formulation partnerships, suggesting collaboration around contract manufacturing and co-development.

Regional footprint Based in Columbus and expanding in Ohio, there is potential to pursue local supplier diversification, regional logistics, and state or local grant program partnerships to optimize production, staffing, and speed-to-market for sterile products.

Growth readiness Revenue estimated in the mid-range of tens of millions with 51-200 employees implies mid-market scale; a targeted outreach to cold-chain logistics providers, QA/QC software vendors, and equipment manufacturers could align with growth plans and ongoing capital expenditure.